psychotropic

Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research.

Phenibut (Aminophenylbutyric acid) is a central depressant and derivative of the naturally occurring inhibitory neurotransmitter γ-aminobutyric acid (GABA).

Phenibut hydrochloride (3-Amino-4-phenylbutyric acid hydrochloride) is a GABA mimetic that acts as an agonist at GABAB receptors, blocks α2δ subunit-containing voltage-gated calcium channels, stimulates dopamine receptors, and inhibits the actions of β-phenethylamine

Abaperidone is a potent 5-HT2A receptor and dopamine D2 receptor antagonist with an IC50 of 6.2 for 5-HT2A receptors and 17 nM for dopamine D2 receptors.Abaperidone is a potentially atypical anti-psychotropic compound that reduces basal hsp70 mRNA expression in rat striatum and prefrontal cortex. expression in the striatum and prefrontal cortex of rats.

Lysergol has been used as a hypotensive, psychotropic analgesic, and uterus- and intestine-stimulating drug. Lysergol is a clavinet alkaloid isolated from seeds of Ipomoea muricata and is a bioenhancer for the drugs and nutrients and has antibacterial act

(Rac)-SEP-363856, the racemate of SEP-363856, is an orally active and CNS-active psychotropic agent with a unique profile.

SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia.

SEP-363856 hydrochloride (SEP-856 hydrochloride) is an orally active, CNS-active psychotropic agent with a unique non-D2/5-HT2A mechanism of action, demonstrating antipsychotic-like effects and potential for schizophrenia treatment.

Adrenochrome (Adraxone) is a cytotoxic molecule that can be used to kill bacteria. Adrenochrome is an oxidized product of Epinephrine. Adrenochrome is a coronary systolic compound that acts on rat hearts and is associated with cardiotoxicity and can be used to determine superoxide dismutase activity. Adrenochrome is a potential psychotropic drug for the study of nervous system diseases.

PRL-8-53, a derivative of 2-Phenylethylamine, functions as an orally active psychotropic agent.

Lofepramine is a serotonin and norepinephrine reuptake inhibitor. Lofepramine is also a psychotropic IMIPRAMINE derivative.

Benanserin HCl is a serotonin antagonist. It causes psychotropic effects in humans.

TC-2153 is a selective inhibitor of striatal-enriched protein tyrosine phosphatase (STEP), exhibiting psychotropic activity and low acute toxicity. It enhances the expression of brain-derived neurotropic factor (BDNF) in the brain, reduces mRNA levels of MAOA and 5-HT1A receptors in the midbrain, and inhibits 5-HT2A receptor-mediated signaling.

UWA-101 hydrochloride is a selective, non-cytotoxic inhibitor of DAT/SERT, demonstrating EC50 values of 3.6 µM for DAT and 2.3 µM for SERT inhibition. It mitigates motor disorders and other side effects associated with dopaminergic agent use (e.g., L-DOPA) without exhibiting psychotropic effects. This compound is utilized in research focused on neurodegenerative conditions like Parkinson's disease [1] [2].

CAY10508 is a potent and selective inverse agonist for the central cannabinoid (CB1) receptor with therapeutic potential for treating obesity and drug dependence, lacking psychotropic effects. It exhibits a Ki value of 243 nM and an EC50 of 195 nM. At a concentration of 10 µM, CAY10508 displaces [3H]-CP-55,940 with 100% efficacy at the CB1 receptor and 35% at the peripheral cannabinoid (CB2) receptor. Its inverse agonist activity at the CB1 receptor was confirmed through a [35S]-GTPγS binding assay.

Geissoschizine methyl ether, a major indole alkaloid found in Uncaria hook, is a key active component of Yokukansan with psychotropic effects. It is a potent serotonin A receptor agonist and a candidate for ameliorating aggressiveness and sociality by Yokukansan.

(±)-Cannabichromene is a major non-psychotropic phytocannabinoid that inhibits endocannabinoid inactivation and activates the transient receptor potential ankyrin-1 (TRPA1), it selectively reduces inflammation-induced hypermotility in vivo in a manner that is not dependent on cannabinoid receptors or TRPA1.